Published in Br J Clin Pharmacol on December 01, 1978
Effect of short surgical procedures on salivary paracetamol elimination. Br J Clin Pharmacol (1985) 0.81
Pharmacokinetics of antipyrine in epileptic patients. Br J Clin Pharmacol (1986) 0.80
Microsomal enzyme induction after halothane anaesthesia. Br J Clin Pharmacol (1981) 0.76
Pharmacological implications of microsomal enzyme induction. Pharmacol Rev (1967) 13.35
Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther (1976) 1.87
Differences in the biotransformation of halothane in man. Anesthesiology (1970) 1.50
Interactions between nutritional factors and drug biotransformations in man. Proc Natl Acad Sci U S A (1976) 1.47
Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther (1975) 1.32
FURTHER STUDIES ON THE INHIBITION AND STIMULATION OF MICROSOMAL DRUG METABOLIZING ENZYMES OF RAT LIVER BY VARIOUS COMPOUNDS. Biochem Pharmacol (1964) 1.32
Halothane-related hepatitis. A clinical study of twenty-six cases. Q J Med (1975) 1.23
Liver dysfunction following abdominal operations; the significance of postoperative hyperbilirubinemia. AMA Arch Intern Med (1950) 1.23
Impaired drug metabolism in rats with adjuvant-induced arthritis: a brief review. Drug Metab Dispos (1974) 1.19
[Interference of diazepam and pentobarbital in the rat and in man]. Naunyn Schmiedebergs Arch Pharmakol (1969) 1.03
Chloroform toxicity in mice: correlation of renal and hepatic necrosis with covalent binding of metabolites to tissue macromolecules. Exp Mol Pathol (1973) 1.01
Quinine disposition during malaria and during induced fever. Clin Pharmacol Ther (1976) 0.99
Metabolic activation of halothane and its covalent binding to liver endoplasmic proteins in vitro. Naunyn Schmiedebergs Arch Pharmacol (1973) 0.94
Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology (1977) 0.92
Mechanism of induction of hepatic microsomal drug metabolizing enzymes by a series of barbiturates. J Pharm Pharmacol (1975) 0.90
Liver injury following halothane anesthesia in phenobarbital-pretreated rats. Biochem Pharmacol (1974) 0.88
Canalicular bile production in man. Eur J Clin Invest (1975) 0.83
In vivo and in vitro studies on irreversible binding of halothane metabolites to proteins. Experientia (1975) 0.82
Induction and inhibition of hepatic drug metabolizing enzymes by rifampin. Biochem Pharmacol (1976) 0.81
Effects of various barbiturates on hepatic microsomal enzymes. A comparative study. Drug Metab Dispos (1975) 0.81
Metabolic activation of trichloroethylene into a chemically reactive metabolite toxic to the liver. J Pharmacol Exp Ther (1978) 0.80
Elimination and distribution of phenylbutazone in rats during the course of adjuvant-induced arthritis. J Pharmacol Exp Ther (1976) 0.78
[Toxicity caused by so-called reactive metabolites of drugs]. Nouv Presse Med (1976) 0.78
Nonspecific stimulation of drug-metabolizing enzymes by inhalation anesthetic agents. Anesth Analg (1971) 0.78
In vivo sequence requirements of the SV40 early promotor region. Nature (1981) 25.00
The ovalbumin gene-sequence of putative control regions. Nucleic Acids Res (1980) 18.04
Ovalbumin gene: evidence for a leader sequence in mRNA and DNA sequences at the exon-intron boundaries. Proc Natl Acad Sci U S A (1978) 14.82
Organisation and sequences at the 5' end of a cloned complete ovalbumin gene. Nature (1979) 9.30
Deletions covering the putative promoter region of early mRNAs of simian virus 40 do not abolish T-antigen expression. Proc Natl Acad Sci U S A (1980) 7.77
Following a diabetogenic T cell from genesis through pathogenesis. Cell (1993) 6.46
Organ-specific disease provoked by systemic autoimmunity. Cell (1996) 6.44
A multiplicity of CCAAT box-binding proteins. Cell (1987) 6.37
Mice lacking MHC class II molecules. Cell (1991) 6.25
Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. Proc Natl Acad Sci U S A (1981) 5.38
From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity (1999) 5.38
Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science (1999) 4.97
beta-Cell death during progression to diabetes. Nature (2001) 4.61
Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43
T helper cell subsets in insulin-dependent diabetes. Science (1995) 3.92
Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med (1999) 3.85
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med (1998) 3.70
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia (2012) 3.70
Induction of altered chromatin structures by simian virus 40 enhancer and promoter elements. Nature (1984) 3.68
The dendritic cell populations of mouse lymph nodes. J Immunol (2001) 3.57
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med (1997) 3.49
Antigen/MHC-specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. Cell (1989) 3.29
Superantigens interact with MHC class II molecules outside of the antigen groove. Cell (1990) 3.20
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Another view of the selective model of thymocyte selection. Cell (1993) 2.85
Several mechanisms can account for defective E alpha gene expression in different mouse haplotypes. Proc Natl Acad Sci U S A (1983) 2.84
Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A (1999) 2.83
CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J Exp Med (1995) 2.70
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology (1999) 2.63
Conserved major histocompatibility complex class II boxes--X and Y--are transcriptional control elements and specifically bind nuclear proteins. Proc Natl Acad Sci U S A (1987) 2.55
Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A (1996) 2.53
Co-evolution from yeast to mouse: cDNA cloning of the two NF-Y (CP-1/CBF) subunits. EMBO J (1990) 2.49
Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg (1991) 2.46
Mice lacking TdT: mature animals with an immature lymphocyte repertoire. Science (1993) 2.42
Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis (1986) 2.39
Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology (1991) 2.38
Targeted complementation of MHC class II deficiency by intrathymic delivery of recombinant adenoviruses. Immunity (1997) 2.38
Cassette vectors directing expression of T cell receptor genes in transgenic mice. J Immunol Methods (1995) 2.37
Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell (1996) 2.32
Mice lacking the MHC class II-associated invariant chain. Cell (1993) 2.30
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Propranolol--a medical treatment for portal hypertension? Lancet (1980) 2.27
How much TCR does a T cell need? Immunity (2001) 2.18
Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon. Lancet (1991) 2.14
Compartmentalization of MHC class II gene expression in transgenic mice. Cell (1988) 2.08
Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology (1980) 2.02
Dominant negative analogs of NF-YA. J Biol Chem (1994) 1.99
Genetic influences on the end-stage effector phase of arthritis. J Exp Med (2001) 1.99
Genetic control of diabetes progression. Immunity (1997) 1.95
An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology (1999) 1.92
A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther (1996) 1.91
Ectopic varices in portal hypertension. Clin Gastroenterol (1985) 1.90
Acute hepatic necrosis and fulminant hepatic failure. Gut (1973) 1.87
The role of CD8+ T cells in the initiation of insulin-dependent diabetes mellitus. Eur J Immunol (1996) 1.87
Properties of a CCAAT box-binding protein. Nucleic Acids Res (1987) 1.85
Second generation (RIBA) test in diagnosis of chronic hepatitis C. Lancet (1991) 1.84
T lymphocytes need IL-7 but not IL-4 or IL-6 to survive in vivo. Int Immunol (2001) 1.82
Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther (1995) 1.78
Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology (1988) 1.76
The shaping of the T cell repertoire. Immunity (2001) 1.75
Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol (1993) 1.72
Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. French Club of Digestive Motility. Eur J Gastroenterol Hepatol (1997) 1.72
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
MHC-linked protection from diabetes dissociated from clonal deletion of T cells. Science (1990) 1.70
The V beta 17+ T cell repertoire: skewed J beta usage after thymic selection; dissimilar CDR3s in CD4+ versus CD8+ cells. J Exp Med (1991) 1.68
Correcting an immune-response deficiency by creating E alpha gene transgenic mice. Nature (1985) 1.67
Damage control, rather than unresponsiveness, effected by protective DX5+ T cells in autoimmune diabetes. Nat Immunol (2001) 1.67
Immune complex type glomerulonephritis in cirrhosis of the liver. Am J Pathol (1975) 1.63
Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription. EMBO J (1992) 1.62
Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology (1985) 1.62
Tetracycline-controllable selection of CD4(+) T cells: half-life and survival signals in the absence of major histocompatibility complex class II molecules. J Exp Med (2000) 1.61
Diterpenoids from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes. Gastroenterology (1997) 1.61
No more than seven interruptions in the ovalbumin gene: comparison of genomic and double-stranded cDNA sequences. Nucleic Acids Res (1979) 1.60
Evolutionary variation of the CCAAT-binding transcription factor NF-Y. Nucleic Acids Res (1992) 1.60
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology (1998) 1.58
Emergency liver transplantation for fulminant hepatitis. Ann Intern Med (1987) 1.56
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology (1994) 1.54
Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc Natl Acad Sci U S A (1997) 1.52
Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology (1991) 1.52
Sclerosing cholangitis induced by formaldehyde solution injected into the biliary tree of rats. Arch Surg (1990) 1.52
Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol (2001) 1.51
Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. Hepatology (1989) 1.50
A controlled study of therapeutic portacaval shunt in alcoholic cirrhosis. Lancet (1976) 1.49
Peliosis hepatis in recipients of renal transplants. Gut (1978) 1.48
Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet (1981) 1.47
A special repertoire of alpha:beta T cells in neonatal mice. EMBO J (1991) 1.47
Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol (1996) 1.46
Polyethylenimine-based intravenous delivery of transgenes to mouse lung. Gene Ther (1998) 1.45
Regulation of N-region diversity in antigen receptors through thymocyte differentiation and thymus ontogeny. Proc Natl Acad Sci U S A (1992) 1.44
Major histocompatibility complex class II molecules can protect from diabetes by positively selecting T cells with additional specificities. J Exp Med (1998) 1.44
Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C. Ann Intern Med (1997) 1.44
Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med (1992) 1.44
The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology (1982) 1.44
Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol (2001) 1.44
A vector driving the expression of foreign cDNAs in the MHC class II-positive cells of transgenic mice. J Immunol Methods (1993) 1.44
Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology (1982) 1.43
The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab (2004) 1.43